Pharmaceutical GMP Terms: A Contextual Glossary

In short: This glossary explains common pharmaceutical manufacturing and quality terms for QA, QC, production and pharmacy learners. WHO collects definitions from different guidelines, so a term can vary by source; check the applicable law, marketing authorization and approved site documents before using a definition operationally.

How to use this glossary

The entries below are concise explanations, not a substitute for a current regulation or a controlled procedure. WHO’s Quality Assurance of Medicines Terminology Database compiles terms from source documents issued across different years and subject areas. It is useful for comparison, but it does not make every entry a universal legal definition.

For related reading, see control of documentation, process validation and good documentation practice under EudraLex Volume 4.

Materials, products and batches

Term	Plain-language meaning
Active pharmaceutical ingredient (API)	A substance used in a finished medicine to provide its intended pharmacological action or another direct therapeutic effect. WHO definitions vary slightly with the product and guideline being discussed.
Starting material	A substance of defined quality used to make a pharmaceutical product; this term excludes packaging materials in the WHO GMP glossary.
Packaging material	Material used to pack a product, including printed components. Primary packaging contacts the product; secondary packaging does not. Transport-only outer packaging is treated separately in the WHO GMP glossary.
Batch or lot	A defined amount of material or product made in one process or a connected series of steps and expected to be sufficiently uniform for its intended processing and control. A batch may be subdivided and later combined where the approved process permits.
Batch number or lot number	A unique combination of letters, numbers or both that identifies a batch across its label and associated records.
Intermediate product	Partly processed material that needs further manufacturing steps before it becomes a bulk product.
Bulk product	Product that has completed processing but has not yet completed final packaging.
Finished product	The dosage form after required manufacturing, final packaging and labelling have been completed.
Pharmaceutical product	In the WHO GMP glossary, a material or product for human or veterinary use that is subject to pharmaceutical legislation in an exporting or importing jurisdiction. The precise legal scope depends on that legislation.
Large-volume parenteral (LVP)	A sterile preparation intended for parenteral use in a single container. The legacy definition in the imported article used a threshold of 100 mL or more.

Manufacturing and facility terms

Term	Plain-language meaning
Manufacture	The wider set of activities for pharmaceutical products, including material purchasing, production, quality control, release, storage, distribution and related controls.
Production	Activities that prepare a product from receipt of materials through processing, packaging and labelling to completion. Its exact scope may be defined differently in a particular GMP document.
Packaging	Operations that turn bulk product into the finished packaged product. WHO’s GMP glossary notes that aseptic filling or filling before terminal sterilisation is not normally treated as packaging.
Clean area	An area designed and operated with defined environmental controls to limit particulate and microbial contamination. Its grade or classification must be taken from the applicable GMP requirements, not inferred from this general definition.
Airlock	A space with two or more doors between rooms, used to help control airflow when people, materials or equipment pass between them.
Self-contained area	A facility area with operational separation, including controls for personnel and equipment movement; some designs also use physical barriers and dedicated air handling. The required degree of separation depends on the applicable product and GMP controls.
Critical operation	A manufacturing step that can affect product quality and therefore needs suitable defined controls. The site’s approved process documents should identify the relevant controls.
Consignment or delivery	A quantity of pharmaceutical products supplied at one time in response to an order. One consignment can contain several batches.

Quality, records and control terms

Term	Plain-language meaning
Quality assurance (QA)	The overall arrangements used to provide confidence that a product will meet its intended quality requirements. WHO describes GMP as one part of the wider quality assurance system.
Quality control (QC)	The part of the quality system concerned with specifications, sampling, testing, documentation and decisions about whether quality requirements have been met.
In-process control	A check made during manufacture to monitor a process and, where authorised, support an adjustment so the product can meet its specifications. Control of relevant equipment or the environment may also form part of in-process control.
Batch records	Records documenting the manufacture and control of a particular batch. Keep batch records for at least 1 year after the expiry date of the respective product batch; EU GMP Part I Chapter 4 §4.11 also requires at least 5 years after certification by the Qualified Person where that period is longer, and 21 CFR 211.180(a) sets the US minimum for records associated with a drug-product batch. Apply any longer period required by local law or the marketing authorization.
Master formula	The approved manufacturing instructions for a product and batch size, including materials, quantities, processing steps, precautions and in-process controls. Terminology differs among GMP sources; use the current controlled document name at the site.
Master record	The approved source record used to prepare or control batch-specific manufacturing documentation. The exact name and content are defined in the applicable quality system.
Specification	A list of tests, methods or references, and acceptance criteria used to judge whether a material or product meets its quality requirements.
Standard operating procedure (SOP)	An approved written instruction for a defined operation, often used for general activities such as equipment use, cleaning, sampling or inspection.
Calibration	Establishing and documenting how an instrument’s indication relates to known reference values under defined conditions. The method and acceptance limits must come from the applicable procedure and equipment use.
Qualification	Documented evidence that premises, systems or equipment are installed and operate as intended. Qualification work can be part of a broader validation programme; it is not, by itself, proof that a manufacturing process is validated.
Validation	Documented evidence that a process, method, system or activity can consistently achieve its intended results under defined conditions. The scope and evidence depend on the subject and applicable guideline.
Marketing authorization	The formal permission granted by a competent authority for a medicine to be marketed in a jurisdiction, with product-specific conditions. Requirements and terminology vary by country.

Material status and process outcomes

Term	Plain-language meaning
Quarantine	A controlled status used to keep materials or products separate while a decision on release, rejection or another authorised disposition is pending.
Reconciliation	Comparing the expected quantity with the actual quantity and documenting the result.
Recovery	Reintroducing suitable material from an earlier batch or process, or recovering material for separate use, at a defined stage. This depends on an authorised process and appropriate quality controls.
Reprocessing	Returning all or part of a batch to an earlier step in the established, validated process after a failure to meet a requirement. Applicable controls and authorisation still govern whether it may be done.
Reworking	Using a different processing route from the established process to address a nonconforming intermediate or product. WHO treats this separately from reprocessing; the term does not itself authorise the activity.
Contamination	Unwanted material, including chemical, microbial or foreign matter, introduced into or onto a material or product.
Cross-contamination	Contamination of one material or product by another during manufacture; the scope in a particular guideline may also cover storage or transport.

Frequently asked questions

Are WHO glossary entries binding everywhere?

No. The WHO database collects terms from individual WHO publications. National law, the marketing authorization and the applicable GMP document determine which definition and requirements apply.

Is reprocessing the same as reworking?

No. In the WHO GMP glossary, reprocessing returns material to a prior validated process step, while reworking follows a different process route. These descriptions do not replace local authorisation or quality-system controls.

How long should batch records be retained?

For the records covered by the cited requirements, retain them at least 1 year after the expiry date of the respective product batch. EU GMP also specifies at least 5 years after Qualified Person certification when longer; US requirements are set out in 21 CFR 211.180(a). Use a longer period when local law or the marketing authorization requires it.

References

World Health Organization (WHO), Quality Assurance of Medicines Terminology Database – List of Terms and related guideline, updated 30 September 2026: WHO publication page and official database PDF.
WHO, WHO Technical Report Series No. 986, Annex 2, “WHO good manufacturing practices for pharmaceutical products: main principles”, 48th WHO Expert Committee report, 2014: official PDF.
European Commission, EudraLex Volume 4, Part I, Chapter 4, “Documentation”, Revision 1, January 2011, §4.11: official PDF.
United States, 21 CFR §211.180(a), “General requirements”, current eCFR: official regulation.